• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Interactio

  2026-05-25

  This study uncovers how naturally occurring angiotensin peptides, especially Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) and its truncated forms, increase SARS-CoV-2 spike protein binding to the AXL receptor. The findings reveal a novel molecular link between the renin–angiotensin system and viral entry mechanisms, with implications for COVID-19 pathogenesis and potential therapeutic targeting.

• Oligomycin A: Precision Mitochondrial ATP Synthase Inhibitor

  2026-05-25

  Oligomycin A from APExBIO empowers researchers to dissect mitochondrial bioenergetics and cancer metabolism with unmatched specificity. This article delivers practical protocols, troubleshooting insights, and advanced applications—bridging recent mechanistic discoveries with robust, reproducible bench workflows.

• KSHV miRNAs Suppress STING to Evade Host Immunity and Delay

  2026-05-24

  Paulsen et al. uncover a mechanism by which Kaposi sarcoma-associated herpesvirus (KSHV) miRNAs directly target and repress STING, a key innate immune sensor, to enable immune evasion and facilitate viral reactivation. These findings clarify how viral miRNAs modulate the cGAS/STING pathway, informing strategies for dissecting viral latency and reactivation using gene expression analysis.

• Jiao-tai-wan/Coptisine Mitigate PCOS via SIRT1 Ubiquitinatio

  2026-05-23

  The reference study reveals that the traditional herbal formula Jiao-tai-wan (JTW) and its component coptisine attenuate polycystic ovary syndrome (PCOS) in rat models by suppressing SIRT1 ubiquitination, thereby normalizing mitochondrial cholesterol import and ovarian steroidogenesis. These mechanistic insights highlight a novel molecular target for PCOS intervention and provide a foundation for future translational research.

• Valemetostat (DS-3201): Dual EZH1/EZH2 Inhibition for Transl

  2026-05-22

  This thought-leadership article explores the mechanistic underpinnings, translational strategies, and future potential of Valemetostat (DS-3201) as a dual EZH1/EZH2 inhibitor in lymphoma and beyond. It integrates new evidence on immunogenic reprogramming, offers protocol guidance, and positions APExBIO’s Valemetostat as a critical tool for innovative epigenetic cancer therapy.

• HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit: Protocol &

  2026-05-22

  The HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit enables high-efficiency, random fluorescent RNA probe synthesis using Cy5-UTP during in vitro transcription. Its optimized T7 RNA polymerase mix supports sensitive applications like in situ hybridization and Northern blotting. This article details the kit's mechanism, evidence base, and workflow integration for reproducible RNA probe labeling.

• Pazopanib (GW-786034): Advanced Protocols for Cancer Researc

  2026-05-21

  Pazopanib (GW-786034) is redefining angiogenesis inhibition in cancer research by enabling precise, reproducible workflows—especially in genetically defined models like ATRX-deficient glioma. Here, we detail stepwise protocols, troubleshooting strategies, and key insights to maximize experimental impact using APExBIO’s trusted reagent.

• Hesperadin: Precision Aurora B Kinase Inhibitor for Cell Cyc

  2026-05-21

  Hesperadin empowers researchers to dissect mitotic progression, spindle assembly checkpoint dynamics, and chromosome segregation with unparalleled specificity. Its ATP-competitive inhibition profile, robust solubility in DMSO, and validated cellular phenotypes make it a gold-standard tool for advanced cancer research and cell cycle assay optimization.

• FITC-Concanavalin A (ConA) Conjugate: Technical Application

  2026-05-20

  FITC-Concanavalin A (ConA) Conjugate provides researchers with a direct, fluorescence-based method for detecting α-D-glucose and α-D-mannose residues on cell surfaces. It is optimized for immunofluorescence, flow cytometry, and glycobiology workflows, but should not be applied to non-carbohydrate-binding assays or outside its defined stability parameters.

• Reserpine (N1867): Technical Guidance for Research Use

  2026-05-20

  Reserpine (SKU N1867) is a high-purity, research-grade natural product for controlled neurotransmitter depletion and antihypertensive mechanism studies, particularly within neuropharmacology workflows. It is not suitable for diagnostic or clinical applications, and best results depend on strict adherence to solubility and storage protocols.

• Caspofungin Workflows: Applied Antifungal Research Excellenc

  2026-05-19

  Caspofungin, a lipopeptide antifungal drug, empowers research labs with selective inhibition of β-(1,3)-D-glucan biosynthesis—crucial for tackling azole-resistant Candida. Explore robust, reproducible experimental workflows, protocol enhancements, and troubleshooting insights to elevate your antifungal research.

• Metformin Hydrochloride: Mechanisms in Glucose and Ossificat

  2026-05-19

  Metformin Hydrochloride (Metformin HCl) acts as a selective AMPK pathway modulator and inhibitor of hepatic gluconeogenesis. Compelling evidence shows it suppresses abnormal bone formation by downregulating the Nr4a1/Wnt/β-catenin signaling axis. This article summarizes its protocol benchmarks, application boundaries, and mechanistic rationale for glucose and bone metabolism research.

• Blue Light Impairs Skin Barrier via EGFR/ERK/c-Jun Pathway

  2026-05-18

  This study provides the first systematic evidence that repeated blue light exposure compromises the skin barrier in humans and mice through activation of the EGFR/ERK/c-Jun signaling cascade. The work elucidates phenotypic and molecular changes, opening avenues for targeted intervention and mechanistic exploration of light-induced skin damage.

• SU 5402: Precision FGFR/VEGFR Inhibition in Human Neuron Mod

  2026-05-18

  Explore how SU 5402 enables advanced receptor tyrosine kinase inhibition in complex human neuron models. This article uniquely connects SU 5402's molecular mechanisms with cutting-edge latent HSV-1 infection research, providing deep, actionable insights for translational scientists.

• PD0325901: MEK Inhibitor Workflows for Tumor Suppression

  2026-05-17

  PD0325901 empowers cancer researchers with precise MEK pathway inhibition, enabling robust apoptosis induction and tumor growth suppression in preclinical models. This guide delivers protocol enhancements, troubleshooting strategies, and insights drawn from cutting-edge stem cell signaling research.

15220 records 1/1015 page Next 12345 下5页 Last page